An antibody treatment developed at Stanford Medicine successfully prepared patients for stem cell transplants without toxic busulfan chemotherapy or radiation, a phase 1 clinical trial has shown.
Please provide your email address to receive an email when new articles are posted on . Researchers report positive results from a phase 1b/2a placebo-controlled study of DISC-0974, an ...
Ziltivekimab, an anti-IL-6 ligand antibody, increases iron and other anemia parameters in patients with chronic kidney disease. Ziltivekimab, a novel anti-IL-6 ligand antibody, improves ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results